IN2014DN08199A - - Google Patents
Info
- Publication number
- IN2014DN08199A IN2014DN08199A IN8199DEN2014A IN2014DN08199A IN 2014DN08199 A IN2014DN08199 A IN 2014DN08199A IN 8199DEN2014 A IN8199DEN2014 A IN 8199DEN2014A IN 2014DN08199 A IN2014DN08199 A IN 2014DN08199A
- Authority
- IN
- India
- Prior art keywords
- cxcl13
- subject
- effective amount
- inhibits
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606049P | 2012-03-02 | 2012-03-02 | |
| PCT/US2013/028602 WO2013130959A1 (en) | 2012-03-02 | 2013-03-01 | Methods for the treatment of b cell-mediated inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08199A true IN2014DN08199A (no) | 2015-05-01 |
Family
ID=47844534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8199DEN2014 IN2014DN08199A (no) | 2012-03-02 | 2013-03-01 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9890213B2 (no) |
| EP (1) | EP2820045B1 (no) |
| JP (1) | JP6193275B2 (no) |
| KR (1) | KR102090969B1 (no) |
| CN (1) | CN104520323B (no) |
| AU (1) | AU2013225812B2 (no) |
| CA (1) | CA2865928C (no) |
| IN (1) | IN2014DN08199A (no) |
| NZ (1) | NZ629828A (no) |
| WO (1) | WO2013130959A1 (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| CA2810217C (en) | 2010-09-02 | 2019-03-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| JP6395606B2 (ja) | 2011-10-11 | 2018-09-26 | バクシネックス インコーポレーティッド | 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| JP6363623B2 (ja) * | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| EP4059516A1 (en) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| US20190169606A1 (en) | 2016-08-02 | 2019-06-06 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| MX2019003019A (es) * | 2016-09-19 | 2019-09-19 | I Mab | Anticuerpos anti-gm-csf y usos de los mismos. |
| BR112020022892A2 (pt) * | 2018-05-31 | 2021-02-23 | Glycom A/S | mistura de hmos para tratamento de doenças autoi-munes |
| SG11202010499UA (en) * | 2018-09-18 | 2020-11-27 | I Mab Biopharma Us Ltd | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
| DK0511011T3 (da) | 1991-04-26 | 1997-03-10 | Surface Active Ltd | Nye antistoffer og fremgangsmåde til anvendelse heraf |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JPH11507224A (ja) | 1995-06-05 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒトケモカインβ−１１およびヒトケモカインα−１ |
| AU4243097A (en) | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20030186889A1 (en) | 2000-03-31 | 2003-10-02 | Wolf-Georg Forssmann | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| AU2002225756A1 (en) | 2000-12-01 | 2002-06-11 | Schering Corporation | Uses of mammalian genes and related reagents |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| AU2003298607B9 (en) | 2002-10-29 | 2011-08-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004045525A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
| US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| AU2004274390A1 (en) | 2003-03-28 | 2005-03-31 | Jacqueline M. Benson | Anti-amyloid antibodies, compositions, methods and uses |
| US20070207166A1 (en) | 2004-04-12 | 2007-09-06 | Genvec, Inc. | Method of Using Adenoviral Vectors to Induce an Immune Response |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| AP2007004034A0 (en) | 2004-12-31 | 2007-06-30 | Genentech Inc | Polypeptides sthat bind br3 and uses thereof |
| WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| WO2007064911A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| BRPI0710636A2 (pt) | 2006-04-21 | 2011-08-23 | Centocor Inc | antagonistas de cxcl 31 e o uso dos mesmos para o tratamento de doenças inflamatórias |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| RU2009140047A (ru) * | 2007-03-30 | 2011-05-10 | Сентокор Орто Байотек Инк. (Us) | Антагонисты cхcl13 и их применение для лечения воспалительных заболеваний |
| US20110300167A1 (en) * | 2008-11-04 | 2011-12-08 | Mcmurry Thomas J | Cxcr5 receptor compounds |
| CA2810217C (en) * | 2010-09-02 | 2019-03-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| US20160002325A1 (en) | 2013-03-08 | 2016-01-07 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
-
2013
- 2013-03-01 IN IN8199DEN2014 patent/IN2014DN08199A/en unknown
- 2013-03-01 EP EP13708639.3A patent/EP2820045B1/en active Active
- 2013-03-01 US US14/382,410 patent/US9890213B2/en active Active
- 2013-03-01 KR KR1020147027747A patent/KR102090969B1/ko active IP Right Grant
- 2013-03-01 NZ NZ629828A patent/NZ629828A/en unknown
- 2013-03-01 CA CA2865928A patent/CA2865928C/en active Active
- 2013-03-01 CN CN201380022683.4A patent/CN104520323B/zh active Active
- 2013-03-01 WO PCT/US2013/028602 patent/WO2013130959A1/en active Application Filing
- 2013-03-01 JP JP2014560085A patent/JP6193275B2/ja active Active
- 2013-03-01 AU AU2013225812A patent/AU2013225812B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865928A1 (en) | 2013-09-06 |
| US20150125467A1 (en) | 2015-05-07 |
| CN104520323A (zh) | 2015-04-15 |
| KR102090969B1 (ko) | 2020-03-19 |
| JP2015509960A (ja) | 2015-04-02 |
| KR20140138830A (ko) | 2014-12-04 |
| AU2013225812B2 (en) | 2017-11-30 |
| CN104520323B (zh) | 2018-05-04 |
| WO2013130959A1 (en) | 2013-09-06 |
| NZ629828A (en) | 2017-05-26 |
| CA2865928C (en) | 2021-02-16 |
| JP6193275B2 (ja) | 2017-09-06 |
| AU2013225812A1 (en) | 2014-09-25 |
| EP2820045A1 (en) | 2015-01-07 |
| US9890213B2 (en) | 2018-02-13 |
| EP2820045B1 (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08199A (no) | ||
| EA201590880A1 (ru) | Композиции и способы лечения протеинопатий | |
| WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
| IN2015KN00414A (no) | ||
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX355648B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| WO2013188813A3 (en) | Novel therapeutics for brain cancer | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| JO3462B1 (ar) | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها | |
| MX2015003048A (es) | Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado. | |
| TW201611843A (en) | Methods of treatment with arginine deiminase | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| DK2714888T3 (da) | Rekombinant gær | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX366046B (es) | Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. | |
| MX343589B (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
| IN2014CN00510A (no) |